Ophthotech Corp is a biopharmaceutical company specializing in the development of novel therapeutics to treat diseases of the back of the eye with a focus on developing therapeutics for age-related macular degeneration.


Updates from The Motley Fool

Latest updates on Ophthotech from Fool.com.
Fovista Flops: What's Next?

Ophthotech's future is in jeopardy following a high-profile phase 3 failure.



Stock Performance

View Interactive OPHT Charts
Sponsored by

Key Data Points

Primary metrics and data points about Ophthotech.
Current Price: $2.48
Prev Close: $2.51
Open: $2.53
Bid: $2.45
Ask: $2.65
Day's Range: $2.45 - $2.54
52wk Range: $2.41 - $65.96
Volume: 315,222
Avg Vol 754,319
Market Cap: $89M
P/E (ttm): -0.45
EPS (ttm): ($5.62)
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Ophthotech.
CAPS Rating 2 out of 5
 
41 Outperform
6 Underperform
CAPS All Stars
 
9 Outperform
3 Underperform

How do you think Ophthotech will perform against the market?



You pick for Ophthotech is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


Business Summary

Industry, sector and description for Ophthotech.

Ophthotech Corp is a biopharmaceutical company specializing in the development of novel therapeutics to treat diseases of the back of the eye with a focus on developing therapeutics for age-related macular degeneration.

  • Exchange: NASDAQ